A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to Novartis’ ...
Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...
Background and aims Difficulties and errors in the use of maintenance inhalation devices in COPD are common and can result in loss of control and an increased risk of exacerbations, hospitalisation ...
Introduction NVA237 (glycopyrronium) is a safe and effective once-daily inhaled long-acting muscarinic antagonist for the maintenance treatment of COPD. Methods This pooled analysis of the ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Treating Severe Uncontrolled Asthma: Can Single-Inhaler, Fixed Triple-Dose Therapy Improve Outcomes?
Most people with asthma can be effectively managed with an inhaled corticosteroid (ICS), alone or in combination with a long-acting β2-agonist (LABA). However, a significant number of patients with ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results